Hadean Ventures

Gesynta Pharma AB is a clinical-stage pharmaceutical company based in Solna, Sweden, focused on developing innovative treatments for chronic inflammatory conditions through the inhibition of the pro-inflammatory enzyme microsomal prostaglandin E synthase-1 (mPGES-1). Originating from research at Karolinska Institutet, the company's most advanced drug candidate, vipoglanstat (GS-248), is being developed as a non-hormonal treatment for endometriosis, a prevalent and painful condition affecting many women of reproductive age. In preclinical studies, vipoglanstat has shown significant reductions in endometriotic lesions, pain relief, and improved well-being, with plans for a clinical phase II study underway. Additionally, Gesynta Pharma is preparing to advance another drug candidate, GS-073, into clinical phase I for a different inflammatory condition in 2023. The company aims to provide safe and effective treatment options for patients facing serious diseases related to chronic inflammation. Founded in 2017, Gesynta Pharma is supported by various investors, including Hadean Ventures, Industrifonden, and Linc.

SciRhom GmbH is a biotech company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening autoimmune diseases. Based on longstanding academic research and a well-established network of experts, SciRhom was founded in 2016 through a collaboration between academic and industry scientists with profound experience in antibody development.

ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successful development of our products.

Complement Therapeutics is a preclinical stage biotechnology company focused on developing a precision medicine diagnostic platform to address chronic diseases associated with the dysregulation of the complement system. The company's innovative platform enables the stratification of patients based on their complement-activation profiles, which has the potential to enhance patient selection for clinical trials and serve as an efficacy biomarker in future studies. By offering a more tailored approach to treatment, Complement Therapeutics aims to improve medical outcomes for patients suffering from these chronic conditions.

Alex Health AB, based in Stockholm, is an innovative AI and psychology startup dedicated to improving mental health through behavioral change. Founded in 2017, the company is currently developing a second-generation app aimed at helping one billion individuals overcome detrimental habits. Alex Therapeutics, its digital therapeutics division, focuses on enhancing clinician support for patients struggling with unwanted behaviors that negatively impact their health. Utilizing a proprietary AI platform, the company creates CE-marked software medical devices for various therapeutic areas, including obesity, breast cancer, and nicotine addiction. By combining psychology, design, and technology, Alex Health offers evidence-based digital interventions that provide personalized care and self-healthcare solutions, paving the way for more accessible healthcare. The company is located at Norrsken House in Stockholm.

Alex Health AB, based in Stockholm, is an innovative AI and psychology startup dedicated to improving mental health through behavioral change. Founded in 2017, the company is currently developing a second-generation app aimed at helping one billion individuals overcome detrimental habits. Alex Therapeutics, its digital therapeutics division, focuses on enhancing clinician support for patients struggling with unwanted behaviors that negatively impact their health. Utilizing a proprietary AI platform, the company creates CE-marked software medical devices for various therapeutic areas, including obesity, breast cancer, and nicotine addiction. By combining psychology, design, and technology, Alex Health offers evidence-based digital interventions that provide personalized care and self-healthcare solutions, paving the way for more accessible healthcare. The company is located at Norrsken House in Stockholm.

TargED Biopharmaceuticals is a biotechnology company focused on developing innovative biological drugs aimed at enhancing the treatment of thrombosis. The company utilizes small antibodies, known as VhH, to deliver enzymes directly to the sites of thrombus, facilitating targeted thrombolysis. This approach allows for effective treatment regardless of the blood clot's composition, thereby enabling healthcare professionals to accelerate patient care and improve outcomes for those affected by thrombosis.

Ribbon Biolabs GmbH, founded in 2018 and based in Vienna, Austria, specializes in the synthesis of long deoxyribonucleic acid (DNA) molecules. The company employs innovative techniques to produce DNA of unprecedented lengths, setting new standards in molecular biology. Its services cater to the diverse needs of synthetic biology, supporting researchers and companies in various applications, including genome construction, high-throughput library creation, and the development of DNA-based products and nanotechnology devices. By enabling the synthesis of long DNA sequences without economic or time constraints, Ribbon Biolabs aims to advance the next wave of biotechnologies and facilitate cutting-edge research in genetic solutions.

Emergence Therapeutics AG is a biopharmaceutical company based in Duisburg, Germany, focused on developing novel antibody-drug conjugate (ADC) immuno-therapeutics for high-need cancers. Founded in 2019, the company is advancing its lead program, which combines a highly specific antibody with optimized linker and payload technology to target Nectin-4, a clinically validated target for various cancers. This approach is inspired by the success of enfortumab vedotin, an approved treatment for urothelial cancers. Emergence Therapeutics is also exploring opportunities to create additional first- or best-in-class ADCs, aiming to address significant therapeutic needs in oncology.

Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, established in 2016. The company specializes in the development of non-coding RNA-based therapeutics aimed at treating and preventing heart disease, a leading cause of mortality in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a molecular master switch (microRNA) responsible for pathological changes in the heart resulting from stress or injury. By advancing innovative therapies, Cardior Pharmaceuticals aims to address significant health challenges associated with cardiovascular conditions.

SAGA Diagnostics AB is a company specializing in molecular genetic tests and services aimed at enhancing cancer diagnostics and disease monitoring for healthcare providers, biopharmaceutical firms, and academic institutions. Founded in 2016 as a spin-out from a research group at Lund University, SAGA focuses on the analysis of circulating tumor DNA (ctDNA), a critical biomarker for cancer. The company offers a range of services, including gene mutation analysis, chromosome analysis, and non-invasive liquid biopsy testing, which allows for the ultrasensitive detection of actionable mutations. SAGA's proprietary technology supports oncologists and drug developers by enabling the stratification of patient groups and monitoring treatment responses, thereby facilitating more precise cancer medicine and improving patient outcomes. Based in Lund, Sweden, SAGA is driven by a team of experienced scientists and professionals dedicated to advancing cancer research and clinical diagnostics.

Oncoinvent AS is a company focused on developing innovative cancer treatments by utilizing established physical and chemical principles in the application of novel materials. Their approach aims to enhance medical benefits while reducing safety concerns associated with these treatments. By creating pharmaceutical products specifically designed for the healthcare sector, Oncoinvent seeks to provide effective therapeutic options for cancer patients, contributing to improved patient outcomes in the field of oncology.

Step Pharma, established in 2014 and based in Paris, France, focuses on developing innovative small molecule therapeutics for immunosuppressive therapies aimed at treating autoimmune diseases. As a spin-off from the Imagine Institute, the company leverages research on genetic immunodeficiencies conducted by Pr. Alain Fischer. Step Pharma operates as a joint venture with contributions from Imagine, Sygnature Discovery, and Kurma Partners, combining expertise in drug discovery and funding within the healthcare and biotechnology sectors. The company's proprietary therapeutics utilize a novel class of oral nucleotide synthesis inhibitors that specifically target cytidine triphosphate synthase 1 (CTPS1). This targeted approach enables selective modulation of immune cell populations, such as T and B cells, leading to enhanced treatment efficacy and improved therapeutic outcomes for patients with autoimmune conditions.

Pipeline Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases. The company's therapies leverage the natural repair process in several different nervous system cell types to target diseases such as multiple sclerosis, providing patients with a treatment to repair damage to the nervous system.

CardioMech is a Norwegian company focused on developing therapeutic devices for structural heart disease, specifically aimed at providing a transcatheter alternative to traditional cardiac surgery. Founded in 2015 and headquartered in Trondheim, the company specializes in catheter-based technology that facilitates the placement of artificial chords for the mitral valve. This innovative approach allows surgeons to address severe symptomatic degenerative mitral regurgitation (DMR) caused by conditions such as prolapse or flail, without the need for open-heart surgery. By enabling minimally invasive procedures, CardioMech's devices offer new therapeutic options for patients suffering from moderate to severe mitral regurgitation, thereby improving treatment outcomes while reducing the risks associated with more invasive surgical methods.

Gesynta Pharma AB is a clinical-stage pharmaceutical company based in Solna, Sweden, focused on developing innovative treatments for chronic inflammatory conditions through the inhibition of the pro-inflammatory enzyme microsomal prostaglandin E synthase-1 (mPGES-1). Originating from research at Karolinska Institutet, the company's most advanced drug candidate, vipoglanstat (GS-248), is being developed as a non-hormonal treatment for endometriosis, a prevalent and painful condition affecting many women of reproductive age. In preclinical studies, vipoglanstat has shown significant reductions in endometriotic lesions, pain relief, and improved well-being, with plans for a clinical phase II study underway. Additionally, Gesynta Pharma is preparing to advance another drug candidate, GS-073, into clinical phase I for a different inflammatory condition in 2023. The company aims to provide safe and effective treatment options for patients facing serious diseases related to chronic inflammation. Founded in 2017, Gesynta Pharma is supported by various investors, including Hadean Ventures, Industrifonden, and Linc.

Oncoinvent AS is a company focused on developing innovative cancer treatments by utilizing established physical and chemical principles in the application of novel materials. Their approach aims to enhance medical benefits while reducing safety concerns associated with these treatments. By creating pharmaceutical products specifically designed for the healthcare sector, Oncoinvent seeks to provide effective therapeutic options for cancer patients, contributing to improved patient outcomes in the field of oncology.

Neuro Event Labs is a Finnish medical technology growth company. The company’s main product monitors epilepsy patients at home and in hospital. Accurate epilepsy seizure data is collected, analyzed and relayed to the patient’s physician, who makes individual treatment decisions based on the reports. The solution has been developed on close cooperation with leading Finnish hospitals.

Abliva AB is a Swedish pharmaceutical company dedicated to the research and development of treatments for primary mitochondrial diseases, which are rare and severe disorders caused by dysfunctional mitochondria responsible for cellular energy production. The company's development pipeline includes KL1333, currently in phase I clinical trials, which acts as a regulator of NAD+ and NADH, and has received orphan drug designation in both Europe and the United States. Additionally, Abliva is preparing to initiate clinical trials for NV354, an energy replacement therapy that has recently completed preclinical development. The company also focuses on NeuroSTAT, aimed at treating traumatic brain injuries. Collaborations with various institutions and organizations, including Isomerase and the University of Pennsylvania, enhance its research capabilities. Founded in 2000 and headquartered in Lund, Sweden, Abliva was previously known as NeuroVive Pharmaceutical AB until its name change in May 2020.

Pipeline Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases. The company's therapies leverage the natural repair process in several different nervous system cell types to target diseases such as multiple sclerosis, providing patients with a treatment to repair damage to the nervous system.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company based in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead candidate, MV-CHIK, has successfully completed Phase II clinical trials for chikungunya treatment. Themis is also advancing vaccines targeting other infectious diseases, including Zika virus, Lassa fever, and MERS, along with developing therapeutics for cancer. Themis has established a research collaboration and exclusive licensing agreement with Merck & Co., enhancing its capabilities and market reach. The company is focused on progressing its innovative vaccine candidates through various clinical development phases while positioning itself as a valuable partner in the biotech and pharmaceutical sectors.

SAGA Diagnostics AB is a company specializing in molecular genetic tests and services aimed at enhancing cancer diagnostics and disease monitoring for healthcare providers, biopharmaceutical firms, and academic institutions. Founded in 2016 as a spin-out from a research group at Lund University, SAGA focuses on the analysis of circulating tumor DNA (ctDNA), a critical biomarker for cancer. The company offers a range of services, including gene mutation analysis, chromosome analysis, and non-invasive liquid biopsy testing, which allows for the ultrasensitive detection of actionable mutations. SAGA's proprietary technology supports oncologists and drug developers by enabling the stratification of patient groups and monitoring treatment responses, thereby facilitating more precise cancer medicine and improving patient outcomes. Based in Lund, Sweden, SAGA is driven by a team of experienced scientists and professionals dedicated to advancing cancer research and clinical diagnostics.

Nisonic is a medical technology company focused on developing innovative products for the non-invasive diagnosis and monitoring of increased intracranial pressure (ICP). The company's advanced ultrasound technology utilizes an optimized transducer for transorbital imaging and employs machine-learning algorithms to provide automatic measurements and guidance for accurate probe positioning. This approach enables medical professionals in emergency departments, intensive care units, and critical care settings to detect ICP early and intervene effectively, thereby reducing the reliance on invasive methods that carry risks of complications and are limited to larger hospitals. By integrating their software with existing ultrasound devices, Nisonic aims to enhance the accessibility and cost-effectiveness of ICP monitoring, ultimately improving patient outcomes and lowering mortality and disability rates associated with elevated intracranial pressure.

Attgeno is a pharmaceutical company focused on developing treatments for acute, life-threatening conditions. The company specializes in nitric oxide-donating drugs that are designed to selectively target and reduce elevated blood pressure in the lungs. Their innovative drug utilizes nitric oxide-containing substances with distinct properties that facilitate the delivery of the medication directly to the lungs. By promoting the expansion of blood vessels in this area, Attgeno's treatment aims to effectively lower pulmonary pressure, thereby providing healthcare professionals with a valuable tool to manage critical health situations in their patients.